Pharmaceuticals

Neupogen (filgrastim) Market 2026–2030: Forecasting Business Opportunities Ahead

March 6, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the neupogen (filgrastim) market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Neupogen (filgrastim) Market in 2030?

The neupogen (filgrastim) market has experienced robust growth in recent years. It is projected to increase from $1.4 million in 2025 to $1.48 million in 2026, achieving a compound annual growth rate (CAGR) of 5.5%. This historical expansion can be attributed to factors such as increased chemotherapy utilization, the high infection risk faced by neutropenic patients, the clinical validation of g-csf therapy, hospital-centered cancer care approaches, and the limited availability of early treatment options.

The market size for neupogen (filgrastim) is anticipated to experience substantial growth in the coming years. It is projected to expand to $1.81 million by 2030, demonstrating a compound annual growth rate (CAGR) of 5.2%. This expected growth during the forecast period stems from factors such as increasing instances of cancer, wider adoption of biosimilars, an increase in outpatient oncology services, improved availability of biologic therapies, and a focus on preventing infections. Prominent trends throughout the forecast period include a rising emphasis on supportive care in oncology, the expansion of management strategies for chemotherapy-induced neutropenia, greater acceptance of biologic growth factors, a shift towards outpatient neutropenia treatment, and the increasing use of biosimilar alternatives.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19910&type=smp

What Drivers Are Influencing Production Trends In The Neupogen (filgrastim) Market?

The expanding occurrence of diverse illnesses is anticipated to fuel the future expansion of the neupogen (filgrastim) market. These conditions represent bodily irregularities in structure or function, leading to distinct symptoms or impacting particular areas, frequently resulting from infections, genetic predispositions, environmental elements, or lifestyle decisions. The growing frequency of these ailments stems from contributing factors like demographic aging, inactive lifestyles, heightened pollution, inadequate diets, and the worldwide dissemination of infectious agents. Neupogen (filgrastim) tackles issues arising from chemotherapy-induced neutropenia by boosting neutrophil production, thus strengthening the immune system’s capacity to fight infections in individuals with compromised immunity. This treatment plays a vital role in lowering hospitalization figures, mitigating infection dangers, and enabling continuous cancer treatment plans for patients undergoing rigorous therapies. For example, data from Allergy UK, a national charity in the UK, indicated in April 2024 that over 21 million people in the UK suffer from allergies, marking it as the most common chronic health condition in 2022, with forecasts suggesting that by 2026, half of Europe’s population will have experienced at least one allergy. Furthermore, in June 2022, Macmillan Cancer Support, a UK-based cancer charity, reported that 3 million individuals were living with cancer in the UK, a number expected to increase to almost 3.5 million by 2025 and 4 million by 2030. Consequently, the rising occurrence of diverse illnesses is a key factor propelling the expansion of the neupogen (filgrastim) market.

Which Segments Are Gaining Traction In The Neupogen (filgrastim) Market?

The neupogen (filgrastim) market covered in this report is segmented –

1) By Drug Type: Biologic, Biosimilar

2) By Indication: Chemotherapy Induced Neutropenia, Chronic Neutropenia, Others

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Which Competitive Trends Are Impacting The Structure Of The Neupogen (filgrastim) Market?

Companies operating in the neupogen (filgrastim) market are increasingly prioritizing the development of innovative filgrastim biosimilar products, aiming to offer a cost-effective and accessible solution for managing chemotherapy-induced neutropenia. Filgrastim biosimilars are biological medicines designed to closely resemble the original filgrastim (Neupogen) in terms of safety, efficacy, and structure, and are primarily used to stimulate neutrophil production in patients undergoing chemotherapy to prevent neutropenia. For example, in September 2024, Tanvex BioPharma, a U.S.-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Nypozi (filgrastim-txid), a biosimilar referencing Amgen’s Neupogen. Nypozi was one of three biosimilars cleared by the FDA on the same day, contributing to a total of 55 biosimilars approved in the United States as of June 2024. It is indicated for reducing the incidence of infection, particularly febrile neutropenia, in patients with non-myeloid malignancies who are receiving myelosuppressive anticancer drugs.

Who Are The Core Companies Influencing Trends In The Neupogen (filgrastim) Market?

Major companies operating in the neupogen (filgrastim) market are Amgen Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/neupogen-filgrastim-global-market-report-

Which Regions Are Projected To Dominate The Neupogen (filgrastim) Market In The Coming Years?

North America was the largest region in the neupogen (filgrastim) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neupogen (filgrastim) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Neupogen (filgrastim) Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19910&type=smp

Browse Through More Reports Similar to the Global Neupogen (filgrastim) Market 2026, By The Business Research Company

Biopreservation Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopreservation-global-market-report

Nematicides Market Report 2026

https://www.thebusinessresearchcompany.com/report/nematicides-global-market-report

Nebulizers Market 2026

https://www.thebusinessresearchcompany.com/report/nebulizers-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795